Vistagen Therapeutics, Inc.
VTGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001411685
No open-market purchases or sales by Vistagen Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $2.54M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Vistagen Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 54 | 48 | −6 |
| Shares | 15.5M | 15.9M | +421.2K (+2.7%) |
| Value | $44.9M | $39.0M | −$5.83M (−13.0%) |
New holders (3)
Institutions that held Vistagen Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Dimensional Fund Advisors LP | 17,545 | $43.9K | 0.00% |
| Cubist Systematic Strategies, LLC | 10,088 | $25.2K | 0.00% |
| Barclays PLC | 1 | $3 | 0.00% |
Sold out (9)
Institutions that held Vistagen Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Goldman Sachs Group Inc | 194,533 | $573.9K |
| Squarepoint Ops LLC | 107,744 | $317.8K |
| Landscape Capital Management, L.L.C. | 41,804 | $123.3K |
| Millennium Management LLC | 38,732 | $114.3K |
| Man Group plc | 18,338 | $54.1K |
| R Squared Ltd | 8,610 | $25.4K |
| Caption Management, LLC | 4,460 | $13.2K |
| BFSG, LLC | 1,000 | $2.95K |
| Tower Research Capital LLC (TRC) | 223 | $658 |